Leerink Partnrs Issues Negative Forecast for IDXX Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Research analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for IDEXX Laboratories in a research report issued on Thursday, May 1st. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings per share of $3.03 for the quarter, down from their prior forecast of $3.04. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $11.93 per share. Leerink Partnrs also issued estimates for IDEXX Laboratories’ Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $12.04 EPS.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period in the previous year, the business earned $2.71 EPS. The company’s revenue was up 3.6% compared to the same quarter last year.

IDXX has been the topic of several other research reports. Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a research report on Monday, April 14th. Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Finally, StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $524.75.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $475.07 on Monday. The stock’s 50-day simple moving average is $419.61 and its 200 day simple moving average is $428.18. IDEXX Laboratories has a 52-week low of $356.14 and a 52-week high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a market cap of $38.50 billion, a P/E ratio of 44.52, a P/E/G ratio of 3.41 and a beta of 1.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IDXX. Norges Bank acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at approximately $412,258,000. GAMMA Investing LLC raised its position in IDEXX Laboratories by 59,810.7% during the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company’s stock valued at $3,856,950,000 after purchasing an additional 916,898 shares in the last quarter. Flossbach Von Storch SE lifted its stake in IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of IDEXX Laboratories by 58.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock valued at $472,865,000 after purchasing an additional 414,802 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $156,412,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.